Azilect FDA Approval History
FDA Approved: Yes (First approved May 16, 2006)
Brand name: Azilect
Generic name: rasagiline mesylate
Dosage form: Tablets
Previous Name: Agilect
Company: Teva Pharmaceutical Industries Ltd.
Treatment for: Parkinson's Disease
Azilect (rasagiline) is a monoamine oxidase -B inhibitor administered once-daily as initial monotherapy in early Parkinson's Disease (PD) and as adjunct therapy to levodopa in moderate-to-advanced disease.
Development timeline for Azilect
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
